Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis

• Status: Unknown status
• Trial end date: 2020-08-24
• Target enrollment: 0
• Participant gender: All

Summary

The incidence rate of gastric cancer is high in Southeast Asia, so is the mortality rate.Due to the lack of specific performance, about 5%-20% of patients have found peritoneal metastases at the time of first diagnosis.At present, clinical studies on HIPEC in the treatment of patients with advanced gastric cancer peritoneal metastasis are almost related to abdominal perfusion after laparoscopic gastrectomy.Herein, we conduct a single-centre randomized controlled trial to explore the safety and feasibility of laparoscopic exploration combined with HIPEC in the treatment of advanced gastric cancer with peritoneal metastasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine
• Treatments: Oxaliplatin

Criteria

Inclusion Criteria:

• Primary gastric adenocarcinoma diagnosed pathologically by endoscopic biopsy；

• Laparoscopic exploration of patients with advanced gastric adenocarcinoma of peritoneal metastasis；

• Eastern Cooperative Oncology Group (ECOG): 0 ot 1；

• American Society of Anesthesiologists （ASA） score: I to Ⅲ；

• Patient informed consent。

Exclusion Criteria:

• Pregnancy or female in suckling period；

• Severe mental illness；

• Preoperative imaging or intraoperative exploration reveals distant blood, liver, lung, and brain metastases；

• 5 years of history of other malignant diseases；

• A history of unstable angina or myocardial infarction within 6 months；

• History of cerebral infarction or cerebral hemorrhage within 6 months；

• A history of sustained systemic corticosteroid treatment within 1 month；

• Emergency operation due to complication (bleeding, perforation or obstruction) caused by primary tumor；

• Pulmonary function test FEV1